Annual General Meeting 2025: ANGLE plc Reports All Resolutions Passed
GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc, a global frontrunner in liquid biopsy technology, announced today that all resolutions put forth at its Annual General Meeting, held earlier today, were approved by shareholders. This marks a significant procedural milestone for the company.
Detailed voting outcomes are expected to be published on the company’s website in the near future.
ANGLE plc is carving out a distinct niche in the healthcare sector with its innovative circulating tumor cell (CTC) solutions. These advanced technologies are designed for critical applications in research, drug development, and clinical oncology, all derived from a simple blood sample. The company’s FDA-cleared and patent-protected Parsortix® PC1 System stands as a testament to its commitment to pushing the boundaries of diagnostic capabilities. This system facilitates comprehensive downstream analysis, encompassing whole-cell imaging, proteomic profiling, and in-depth genomic and transcriptomic molecular analysis.
The company’s commercial strategy is bifurcated, focusing on clinical services and diagnostic products. ANGLE’s clinical services are delivered through state-of-the-art, GCLP-compliant laboratories, offering bespoke assay development and clinical trial testing for pharmaceutical partners. Complementing these services, ANGLE provides its innovative Parsortix system, along with associated consumables and assays.
With over 100 peer-reviewed publications underscoring the performance of the Parsortix system, ANGLE plc is solidifying its position as a key player in the evolving landscape of cancer diagnostics. Investors and stakeholders can find more information at www.angleplc.com.
SOURCE: ANGLE plc
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3692.html
